All Pharma News
price-trendAsk Us
FDA says it needs a little more time to decide on Merck`s P2X3 for chronic cough

FDA says it needs a little more time to decide on Merck`s P2X3 for chronic cough
ENDPTS
13 Aug 2021
Share Share
2 pathways deal a one-two punch to melanoma cells

2 pathways deal a one-two punch to melanoma cells
Kyle LaHucik FIERCEBIOTECH
19 Jul 2021
Share Share
Merck partners with Innervia on bioelectronic therapy development

Merck partners with Innervia on bioelectronic therapy development
PHARMATIMES
08 Jul 2021
Share Share
Gilead files long-acting HIV med for patients with few options

Gilead files long-acting HIV med for patients with few options
FIERCEBIOTECH
30 Jun 2021
Share Share
Metabolon Announces Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany

Metabolon Announces Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany
PRNEWSWIRE
03 Aug 2020
Share Share
Germany`s Merck seeks partners for cancer and immune system drugs

Germany`s Merck seeks partners for cancer and immune system drugs
Ludwig Burger REUTERS
21 Apr 2018
Share Share
Merck Begins Tender Offer to Acquire Cubist

Merck Begins Tender Offer to Acquire Cubist
PRESS RELEASE
19 Dec 2014
Share Share
Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers

Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers
PRESS RELEASE
18 Dec 2014
Share Share
Bayer fails last-ditch attempt to block India`s cheap Nexavar copies

Bayer fails last-ditch attempt to block India`s cheap Nexavar copies
Emily Wasserman Fierce Pharma
15 Dec 2014
Share Share
Did Merck Pay $3B Too Much For Cubist? Weighing the Impact of Cubicin Patent Loss

Did Merck Pay $3B Too Much For Cubist? Weighing the Impact of Cubicin Patent Loss
Tracy Staton Fierce Pharma
09 Dec 2014
Share Share